zcompetition

The Competition

A number of new technologies are under development to improve the
treatment of chronic progressive lung disease that may reduce lung
fibrosis. In addition, there are several ongoing clinical programs with
PTHrP agonists/antagonists that may become available for
non-pulmonary indications, but nevertheless have potential off-label use
in the treatment of pulmonary fibrosis. For example, interferon
gamma-1b is believed to be superior to corticosteroids based on
preliminary studies, although its cost ($100,000 per patient year) is
prohibitive for most individuals.

Drug	Company	Mechanism	Indication	Status
Interferon-alpha	Biogen / IDEC	Interferon alpha agonist	Pulmonary fibrosis	Clinical Phase II
Pirfenidone	Intermune	Collagenase and cytokine inhibitor	Idiopathic pulmonary fibrosis	Clinical Phase II
Alpha-antitrypsin	Bayer	Protease inhibitor	Idiopathic pulmonary fibrosis	Clinical Phase II
Sivelestat	Ono	Leucocyte elastase inhibitor	Idiopathic pulmonary fibrosis	Clinical Phase III
Valsartan	Novartis	Angiotensin II antagonist	Pulmonary fibrosis	Preclinical
Tetrathionoly- bdate	Attenuon	FGF antagonist	Pulmonary fibrosis	Preclinical
GC-1008	Genzyme / Cambridge AB	TGF-beta antagonist	Pulmonary fibrosis	Preclinical
Connective Tissue Growth Factor inhibitor	Fibrogen	CTGF inhibitor	Pulmonary fibrosis (IPF), renal, hepatic fibrosis	Preclinical